TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cogstate Ltd ( (AU:CGS) ) just unveiled an announcement.
Cogstate Ltd held its inaugural Shareholder Day, highlighting its role as a digital disruptor in CNS disease clinical trials. The event showcased Cogstate’s technology solutions, strategic partnerships, and market growth opportunities. Key announcements included a strategic partnership with Medidata to enhance CNS clinical trials through AI and advanced analytics, and a projected growth of its CNS clinical trial solutions segment to $1.0–$1.3 billion by 2030. Cogstate is also expanding into new therapeutic areas and enhancing its technology and data quality capabilities to remain competitive and responsive to industry needs.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$3.00 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd (ASX: CGS) is a neuroscience technology company focused on optimizing brain health assessments to advance new medicine development and enable earlier clinical insights in healthcare. The company provides rapid, reliable, and sensitive computerized cognitive tests and supports partners with electronic clinical outcome assessment (eCOA) solutions. Cogstate’s clinical trials solutions include quality assurance services, advanced analytics, and scientific consulting, serving biopharmaceutical companies, academic institutions, and healthcare providers globally.
Average Trading Volume: 248,898
Technical Sentiment Signal: Buy
Current Market Cap: A$473.7M
See more data about CGS stock on TipRanks’ Stock Analysis page.